PureTech Health plc (LON:PRTC)
London · Delayed Price · Currency is GBP · Price in GBX 113.99
-1.01 (-0.88%)
Mar 26, 2026, 8:16 AM GMT
PureTech Health Employees
PureTech Health had 56 employees as of December 31, 2024. The number of employees decreased by 34 or -37.78% compared to the previous year.
Employees
56
Change (1Y)
-34
Growth (1Y)
-37.78%
Revenue / Employee
83.30K GBP
Profits / Employee
660.53K GBP
Market Cap
279.53M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 56 | -34 | -37.78% |
| Dec 31, 2023 | 90 | -21 | -18.92% |
| Dec 31, 2022 | 111 | 16 | 16.84% |
| Dec 31, 2021 | 95 | -155 | -62.00% |
| Dec 31, 2020 | 250 | -50 | -16.67% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Genus | 3,190 |
| Oxford Nanopore Technologies | 1,335 |
| Oxford Biomedica | 900 |
| hVIVO | 301 |
| Avacta Group | 151 |
| 4basebio | 110 |
| Scancell Holdings | 60 |
| Faron Pharmaceuticals Oy | 33 |
PureTech Health News
- 14 hours ago - PureTech Founded Entity Seaport Therapeutics Announces Publication in Science Translational Medicine Featuring GlyphAllo™ (SPT-300) as the First Triglyceride-Mimetic Prodrug to Achieve Therapeutically Relevant Drug Levels in Humans - Business Wire
- 4 weeks ago - PureTech to Present at the Leerink Partners Global Healthcare Conference - Business Wire
- 4 weeks ago - PureTech Announces Orphan Drug Designations Granted by the U.S. Food and Drug Administration and European Commission for Deupirfenidone (LYT-100) in Idiopathic Pulmonary Fibrosis - Business Wire
- 2 months ago - PureTech to Present at 44th Annual J.P. Morgan Healthcare Conference - Business Wire
- 3 months ago - PureTech Appoints Robert Lyne as Chief Executive Officer - Business Wire
- 3 months ago - PureTech Announces Successful End-of-Phase 2 Meeting with FDA for Deupirfenidone (LYT-100) in Idiopathic Pulmonary Fibrosis - Business Wire
- 3 months ago - PureTech's Founded Entity Gallop Oncology Announces Positive Initial Topline Data from Phase 1b Trial of LYT-200 in Relapsed/Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome - Business Wire
- 5 months ago - PureTech Presents New Phase 2b Analyses Demonstrating Consistent Safety and Efficacy of Deupirfenidone in Older Patients with Idiopathic Pulmonary Fibrosis (IPF), a Historically Undertreated Group - Business Wire